menu
    • menu
    [{"orgOrder":0,"company":"Arrivent","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Furmonertinib","moa":"Pan-EGFR mutant","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Hillhouse Capital Group","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Hillhouse Capital Group"},{"orgOrder":0,"company":"Arrivent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"Pan-EGFR mutant","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Inapplicable"},{"orgOrder":0,"company":"Arrivent","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Furmonertinib","moa":"Pan-EGFR mutant","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Sofinnova Investments","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Sofinnova Investments"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Arrivent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Arrivent","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Arrivent"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Shanghai Allist Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ABK3376","moa":"||EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbisko Therapeutics \/ Shanghai Allist Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Abbisko Therapeutics \/ Shanghai Allist Pharmaceuticals"},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Furmonertinib","moa":"Pan-EGFR mutant","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Furmonertinib","moa":"Pan-EGFR mutant","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arrivent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"Pan-EGFR mutant","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrivent \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Furmonertinib

    Menu

    Furmonertinib

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            InnoCare Pharma

                            China arrow
                            AACR Annual meeting
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ICP-189,Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            InnoCare Doses First Patient In Study Of ICP-189 Combined With Furmonertinib

                            Details : ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, which is being evaluated in combiation with furmonertinib for the treatment of advanced or metastatic non-small cell lung cancer.

                            Product Name : ICP-189

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 28, 2024

                            Lead Product(s) : ICP-189,Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arrivent

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ArriVent Announces Pricing of Upsized Initial Public Offering

                            Details : Proceeds will support NDA approval for furmonertinib, a novel oral EGFR kinase inhibitor with broad activity across EGFR mutations.

                            Product Name : AST2818

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 25, 2024

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arrivent

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $135.7 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Arrivent Unveils $135M IPO Pricing to get Furmonertinib to FDA

                            Details : The net proceeds will be used for the clinical development of (furmonertinib), which focuses on EGFR mutant-selective tyrosine kinase inhibitors that are developed for NSCLC patients.

                            Product Name : AST2818

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 22, 2024

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $135.7 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Arrivent

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced ...

                            Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...

                            Product Name : AST2818

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 30, 2023

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            InnoCare Pharma

                            China arrow
                            AACR Annual meeting
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ICP-189,Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Fur...

                            Details : ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination in combination with furmonertinib, a highly brain-penetrant, broadly active mutation-sele...

                            Product Name : ICP-189

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 13, 2023

                            Lead Product(s) : ICP-189,Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            InnoCare Pharma

                            China arrow
                            AACR Annual meeting
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ICP-189,Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Arrivent

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            InnoCare and ArriVent Announce Clinical Development Collaboration

                            Details : Under the agreement, InnoCare and ArriVent will jointly evaluate the anti-tumor activity and safety of ICP-189, a novel SHP2 allosteric inhibitor, combined with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor, in...

                            Product Name : ICP-189

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 13, 2023

                            Lead Product(s) : ICP-189,Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Arrivent

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Arrivent

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Sofinnova Investments

                            Deal Size : $155.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing

                            Details : The net proceedings will be used to support pivotal Phase 3 and additional studies with the Company’s lead product candidate AST2818 (furmonertinib), a highly brain penetrant, mutant-specific EGFR kinase inhibitor.

                            Product Name : AST2818

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 27, 2023

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Sofinnova Investments

                            Deal Size : $155.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Abbisko Therapeutics

                            China arrow
                            AACR Annual meeting
                            Not Confirmed

                            Abbisko Therapeutics

                            China arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABK3376,Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Shanghai Allist Pharmaceuticals

                            Deal Size : $187.9 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Shanghai's Abbisko Out-Licenses EGFR Candidate in Potentially Nine-Figure Deal

                            Details : The licensed small-molecule antagonist of EGFR ABK3376 is a pre-clinical candidate developed by Abbisko Therapeutics' proprietary drug discovery platform, which is a novel, highly potent, selective, and brain-penetrating new-generation EGFR inhibitor.

                            Product Name : ABK3376

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 03, 2023

                            Lead Product(s) : ABK3376,Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Shanghai Allist Pharmaceuticals

                            Deal Size : $187.9 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Arrivent

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or M...

                            Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...

                            Product Name : AST2818

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 07, 2022

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Arrivent

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Hillhouse Capital Group

                            Deal Size : $150.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            ArriVent Biopharma Launches With Up to $150M in Series A Financing and Strategic Licensing Agreement for Clini...

                            Details : Allist Pharma received approval for furmonertinib in EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) indications in China in March 2021.

                            Product Name : AST2818

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 30, 2021

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Hillhouse Capital Group

                            Deal Size : $150.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth